Vivien Leung1,2, Ya-Lin Chiu3, Donald P Kotler4, Jeanine Albu4, Yuan-Shan Zhu1, Kirsis Ham1, Ellen S Engelson4, Hoda Hammad3, Paul Christos3, Daniel S Donovan5, Henry N Ginsberg5, Marshall J Glesby1,3. 1. a Department of Medicine , Weill Cornell Medical College , New York , NY , USA. 2. e Department of Medicine , Bronx-Lebanon Hospital Center , Bronx , NY , USA. 3. b Department of Healthcare Policy and Research , Weill Cornell Medical College , New York , NY , USA. 4. c Department of Medicine , Mount Sinai St. Luke's-Roosevelt Hospital Center , New York , NY , USA. 5. d Department of Medicine , Columbia University College of Physicians and Surgeons , New York , NY , USA.
Abstract
BACKGROUND/ OBJECTIVE: In a previous report of HIV-infected patients with fat redistribution, we found that recombinant human growth hormone (rhGH) therapy reduced visceral adipose tissue (VAT) but increased insulin resistance, and that the addition of rosiglitazone reversed the negative effects of rhGH on insulin sensitivity. In this study, we sought to determine the effects of rhGH and rosiglitazone therapy on an array of inflammatory and fibrinolytic markers. METHODS:72 patients with HIV-associated abdominal obesity and insulin resistance were randomized to treatment with rhGH, rosiglitazone, the combination of rhGH and rosiglitazone, or placebo for 12 weeks. Subjects with plasma and serum samples available at weeks 0 (n=63) and 12 (n=46-48) were assessed for adiponectin, C-reactive protein, homocysteine, interleukin-1, interleukin-6, tumor necrosis factor alpha, interferon gamma, fibrinogen, plasminogen activator inhibitor-1 antigen, and tissue plasminogen activator antigen. RESULTS: Treatment with both rosiglitazone alone and the combination of rosiglitazone and rhGH for 12 weeks resulted in significant increases in adiponectin levels from baseline. Adiponectin levels did not change significantly in the rhGH arm alone . There were no significant changes in the other biomarkers among the different treatment groups. DISCUSSION: In this study of HIV-infected patients with altered fat distribution, treatment with rosiglitazone had beneficial effects on adiponectin concentrations, an effect that was also seen with a combination of rosiglitazone and rhGH. RhGH administration alone, however, did not demonstrate any significant impact on adiponectin levels despite reductions in VAT.
RCT Entities:
BACKGROUND/ OBJECTIVE: In a previous report of HIV-infectedpatients with fat redistribution, we found that recombinant humangrowth hormone (rhGH) therapy reduced visceral adipose tissue (VAT) but increased insulin resistance, and that the addition of rosiglitazone reversed the negative effects of rhGH on insulin sensitivity. In this study, we sought to determine the effects of rhGH and rosiglitazone therapy on an array of inflammatory and fibrinolytic markers. METHODS: 72 patients with HIV-associated abdominalobesity and insulin resistance were randomized to treatment with rhGH, rosiglitazone, the combination of rhGH and rosiglitazone, or placebo for 12 weeks. Subjects with plasma and serum samples available at weeks 0 (n=63) and 12 (n=46-48) were assessed for adiponectin, C-reactive protein, homocysteine, interleukin-1, interleukin-6, tumor necrosis factor alpha, interferon gamma, fibrinogen, plasminogen activator inhibitor-1 antigen, and tissue plasminogen activator antigen. RESULTS: Treatment with both rosiglitazone alone and the combination of rosiglitazone and rhGH for 12 weeks resulted in significant increases in adiponectin levels from baseline. Adiponectin levels did not change significantly in the rhGH arm alone . There were no significant changes in the other biomarkers among the different treatment groups. DISCUSSION: In this study of HIV-infectedpatients with altered fat distribution, treatment with rosiglitazone had beneficial effects on adiponectin concentrations, an effect that was also seen with a combination of rosiglitazone and rhGH. RhGH administration alone, however, did not demonstrate any significant impact on adiponectin levels despite reductions in VAT.
Entities:
Keywords:
Adiponectin; HIV-1; Human growth hormone; Lipodystrophy; Rosiglitazone
Authors: Jan Frystyk; Christian Berne; Lars Berglund; Karin Jensevik; Allan Flyvbjerg; Björn Zethelius Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: Andreas Knudsen; Terese L Katzenstein; Thomas Benfield; Niklas R Jørgensen; Gitte Kronborg; Jan Gerstoft; Niels Obel; Andreas Kjær; Anne-Mette Lebech Journal: AIDS Date: 2014-05-15 Impact factor: 4.177
Authors: Aina S Lihn; Bjørn Richelsen; Steen B Pedersen; Steen B Haugaard; Gulla Søby Rathje; Sten Madsbad; Ove Andersen Journal: Am J Physiol Endocrinol Metab Date: 2003-07-22 Impact factor: 4.310